
Which Tx Combo Is Best for HER2+ Breast Cancer?
Sara Tolaney, MD, MPH
Sara Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, presented this finding and other interim results of the phase 3 DESTINY-Breast09 study, at the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago.
'Trastuzumab deruxtecan, or T-DXd, in combination with pertuzumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, with a 44% reduction in the risk of disease progression or death when compared to a taxane, trastuzumab, and pertuzumab (THP),' said Tolaney, during her presentation.
New First-line Standard?
Similar results were observed across all patient subgroups, with no new safety signals, Tolaney said.
'These data suggest that T-DXd and pertuzumab may represent a new first-line standard of care for patients with metastatic HER2-positive breast cancer,' she said.
The study randomized 1157 patients to three treatment groups: T-DXd 5.4 mg/kg every three weeks plus placebo, T-DXd-pertuzumab, or a taxane plus trastuzumab with pertuzumab (THP). The interim study readout includes only data from the T-DXd-pertuzumab and the taxane plus trastuzumab with pertuzumab groups.
Pertuzumab + T-Dxd or Standard of Care?
Median progression-free survival (PFS) was 40.7 months in the T-DXd-pertuzumab patients and 26.9 months in the taxane plus trastuzumab with pertuzumab patients ( P < .00001).
Tolaney explained that the study was designed to have an interim analysis for PFS after approximately 399 events across the three arms with at least 277 events for comparison. At the time of the interim analysis, she said, only the TDX-pertuzumab and THP groups met the criteria for superiority, a P -value < .00043, which was not met for the comparison of T-DXd plus placebo to THP. The T-DXd-placebo arm remains blinded until the final progression-free survival analysis, Tolaney said.
Twenty-one percent of the patients in the T-DXd-pertuzumab arm had discontinued T-DXd due to adverse events, Tolaney said; 9% of patients elected to continue with trastuzumab and pertuzumab after they discontinued T-DXd.
Among hormone receptor-positive patients, 13.5% in the T-DXd-pertuzumab group and 38% in the THP group elected to add endocrine treatment. At the data cutoff, 46% of the T-DXd-pertuzumab patients and 33% of those in the THP group remained on study treatment. Median follow-up duration was 29 months.
The treatment effect of T-DXd-pertuzumab became evident early in the study, Tolaney said. Six months after starting treatment, 7% of the T-DXd-pertuzumab group vs 12% of the THP group had progressed. The gap continued to widen over time, she said.
'With 26% of patients still on steady treatment with T-DXd and pertuzumab, it suggests that this median is likely to evolve with further follow-up,' she said.
Objective response rates were also higher with T-DXd–pertuzumab, 86% vs 79% with THP, Tolaney said.
'The complete response rate for T-DXd and pertuzumab was 15%, which was almost double what was seen with THP (8.5%),' she said. Response duration was also longer with T-DXd-pertuzumab, with 73% remaining in response at 24 months vs 55% in the THP arm.
'Overall survival data are very immature at this timepoint with just 16% of survival events seen, but you can see that there is an early trend favoring T-DXd plus pertuzumab with a hazard ratio of 0.84,' she said.
A similar number of patients in both groups had serious treatment-emergent adverse events: 27% for T-DXd-pertuzumab and 25.1% for THP, which Tolaney said, was consistent with the known toxicity profiles of both agents, with no new toxicities identified.
The median duration of treatment in the DESTINY-Breast09 study was 21 months.
'A Pivotal Advancement?'
Rebecca Dent, MD, deputy CEO at the National Cancer Center Singapore, called the DESTINY-Breast09 results 'a pivotal advancement in the treatment of HER2-positive metastatic breast cancer that is both clinically and statistically significant.'
Rebecca Dent, MD
HER2-positive metastatic breast cancer was once considered a 'death sentence,' Dent said at a press conference, but now patients can survive on therapy for years, which presents its own challenges.
Regarding the T-DXd-plus-pertuzumab regimen, Dent said, 'Is this for all patients at the beginning of their treatment for metastatic disease?' The truth of the matter is we don't know.'
Having better biomarkers would provide answers, she said, but for patients with extensive disease with central nervous system metastasis, pertuzumab in combination with other agents 'is clearly your first-line choice.'
How to best sequence therapies is another challenge emerging with these evolving treatment regimens, Dent added. 'And then I think finally we do have to appreciate that there are toxicities: One in terms of quality of life but also cost toxicity,' she said.
Which Therapeutic Regimen Costs More?
Tolaney acknowledged the cost implications of adding pertuzumab to T-DXd, in an interview with Medscape Medical News .
'But I would also note,' Tolaney said, 'that the standard-of-care arm does involve getting continued trastuzumab and pertuzumab therapy.'
In the PATINA study, which added palbociclib (Ibrance) to standard maintenance therapy in patients with HER2-positive metastatic breast cancer, the cost profile was similar to those of the treatments used in the newer trial, Tolaney said.
'You are looking at substantial continued cost because we're continuing to suppress the HER2 pathway for years in these patients,' she said.
AstraZeneca and Daiichi Sankyo funded the study. Tolaney reported financial relationships with ADi, Ambrx, Artios Biopharmaceuticals, Arvinas, AstraZeneca, Bayer, BeiGene, Bicycle Therapeutics, BioNTech, Blueprint Medicines, Bristol Myers Squibb, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR Therapeutics, Eisai, Exelixis, Genentech, Gilead Sciences, Hengrui Pharmaceutical (USA), Immunomedics/Gilead, Incyte, Jazz Pharmaceuticals, Johnson & Johnson, Launch Therapeutics, Lilly, Menarini Group, Merck, Mersana, NanoString Technologies, Natera, Novartis, OncoPep, Pfizer, Reveal Genomics, Sanofi, Seagen, Sumitovant Biopharma, Summit Therapeutics, Systimmune, Tango Therapeutics, Zentalis, Zuellig Pharma, and Zymeworks.
Dent reported having financial relationships with AstraZeneca, Daiichi Sankyo/Astra Zeneca, DKSH, Eisai, Gilead Sciences, Merck Sharpe and Dohme, Novartis, Pfizer, and Roche.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Gwyneth Paltrow is Astronomer's ‘temporary spokesperson' in new video
There's a lot of buzz around Astronomer, the data infrastructure company that skyrocketed into public attention after its executives - now former executives - gave us the viral Coldplay 'kiss cam' moment. With all this recent popularity, the business brought on some extra help, hiring a 'temporary spokesperson' with experience in Coldplay internet fame: Gwyneth Paltrow. Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. 'I've been hired on a very temporary basis to speak on behalf of the 300+ employees at Astronomer,' the actress said in the minute-long video posted to social media Friday. 'Astronomer has gotten a lot of questions over the last few days, and they wanted me to answer the most common ones.' The Goop chief executive happens to be the ex-wife of Coldplay lead singer Chris Martin and co-author of the original 'break-the-internet' breakup statement when the pair announced their 'conscious uncoupling' in 2014. If you're searching for answers to the company's real frequently-asked questions, you won't find them in the tongue-in-cheek clip. The questions 'OMG! What the actual f' and 'How is your social media team holding' get comically cut off by Paltrow as she explained the much less juicy details of Astronomer's business. 'We've been thrilled so many people have a newfound interest in data workflow automation,' Paltrow said. Astronomer's chief executive Andy Byron and human resources chief Kristin Cabot both resigned after they were filmed cuddling at a Coldplay concert in Boston earlier this month. They appeared on the arena video board in a 'kiss cam' segment before looking uncomfortable, with Cabot turning around and Byron ducking out of sight as Martin quipped from the stage that the two might be having an affair. Mark Borkowski, a British public relations and crisis consultant, described using Paltrow to front a video parodying the incident as 'utter genius' that shows the company has a sense of humor. 'It's a savvy use of media to create a viral moment,' he told The Washington Post in a phone interview Saturday. 'In a way you're laughing with everybody else.' Astronomer choosing Paltrow will not go unnoticed, Borkowski said. 'Astronomer is a meme now. Owning the ridiculous nature of how it became a meme is far better than apologizing for it.' A representative for Paltrow didn't immediately respond to a request for comment. As for how he advises clients caught in such situations, Borkowski said acting in a dignified way and 'using as few words as possible' is always the best approach. Paltrow's cameo is reminiscent of the scared Peloton wife discourse from 2019. After actress Monica Ruiz's worry-stricken expression in a Peloton holiday commercial became the butt of internet jokes, she laughed it off, later using her horrified face for an Aviation Gin ad. 'We will now be returning to what we do best: delivering game-changing results for our customers,' Paltrow closed out the ad. 'Thank you for your interest in Astronomer.' - - - Tatum Hunter contributed to this report. Related Content Hulk Hogan was a well-known Trump supporter. Their ties go back 40 years. Mendelson reaches deal with Commanders on RFK site amid growing pressure Amy Sherald cancels major Smithsonian show over 'censorship' Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
How running for 75 minutes a week could help you live longer — and feel younger
When you buy through links on our articles, Future and its syndication partners may earn a commission. It's no secret that regular exercise is good for your health, but new research has uncovered a fascinating link between running and biological aging. In a study of over 4,400 U.S. adults, researchers found that those who jogged or ran for at least 75 minutes per week had significantly longer leukocyte telomeres. That might sound like something out of a science textbook, but it's really just a fancy way of saying your cells look younger on the inside. Telomeres sit at the ends of your chromosomes and act like little caps that protect your DNA. The longer they are, the better off you tend to be when it comes to aging. If you're looking to get started or find the right shoes for your runs, check out our guide to the best running shoes for every type of runner. This Brooks sneaker offers excellent comfort and support for everyday runs. The 27% saving applies to the women's model, but you'll find the same deal on the men's version as well. Just double-check that your size and favorite color are included in the offer before Deal The magic number is 75 minutes a week The study used data from the National Health and Nutrition Examination Survey and grouped people into three categories based on how much they ran each week. Only those who hit 75 minutes or more saw significant benefits to their telomere length, even after researchers controlled for differences in age, lifestyle, and medical history. In fact, the difference was big enough to suggest runners could be roughly 12 years biologically younger than those who don't run regularly. People who ran less than that? Well, they pretty much looked the same as the non-runners. While the results are compelling, it's worth being cautious. The results come from a single snapshot in time and rely on people accurately reporting their exercise, which can sometimes be optimistic. Still, the message is clear and encouraging: making running a regular habit might just be one of the simplest ways to help your cells stay spry. How to make it work for you The best part is that 75 minutes per week breaks down to just over 10 minutes (and 43 seconds if we are being pernickety) a day. That's a realistic goal for many people. If you're just getting started, try alternating walking and running using a beginner-friendly approach like Jeffing. This run-walk method can help you build endurance while easing the impact on your joints. Our fitness editor Jane swapped running for 'Jeffing' for a week and found it surprisingly enjoyable. And if running isn't your thing, other vigorous activities like swimming, cycling, or cardio workouts could offer similar benefits. Whichever route you choose, the science is stacking up in favor of getting your heart rate up. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button. More from Tom's Guide Forget the sauna — soaking in a hot tub could be better for your health, says new study No, not crunches — trainer says these 5 bodyweight moves are the secret to building stronger abs Fibermaxxing is the latest gut health trend, but does it really work?
Yahoo
3 hours ago
- Yahoo
Astronomer CPO Kristin Cabot Resigns After Attending Coldplay Concert With CEO Andy Byron
Astronomer's Chief People Officer has resigned from her position at the tech company after being caught on video at a Coldplay concert with the then-CEO . "Kristin Cabot is no longer with Astronomer," a spokesperson for Astronomer told Us Weekly on Thursday, July 24. "She has resigned." Cabot's life changed forever after she attended Coldplay's concert at Gillette Stadium in Foxboro, Massachusetts, on July 16. During the show, lead singer Chris Martin took a pause from performing to introduce the venue's kiss cam. The jumbotron showed Astronomer executives Cabot and Byron embracing each other before they quickly tried to dodge the cameras when they realized they were onscreen. Astronomer Cofounder Breaks Silence on Andy Byron and Kristin Cabot's Coldplay Kiss Cam Controversy 'Whoa, look at these two. All right, come on. You're OK,' Martin said as the pair tried to hide their faces and escape the camera. 'Either they're having an affair or they're just very shy. I'm not quite sure what to do.' As the camera panned to other audience members — two individuals dressed in banana costumes — Martin had one final thought about what he had just witnessed during his show. 'Holy s***,' he added. 'I hope we didn't do something bad.' Hours after the concert moment was caught on camera, footage began going viral on social media. The internet did some digging and discovered Andy is reportedly married — to a woman multiple outlets identified as — not Cabot. Since the scandal broke, Megan appeared to remove 'Byron' from her Facebook page, according to a screenshot published by Newsweek. She has also deleted her account. Andy resigned from his position as CEO on July 19. Astronomer cofounder Pete DeJoy is now serving as interim CEO. Stars React After Coldplay Jumbotron Seemingly Exposes Affair Between Astronomer Executives Us Weekly previously reached out to Astronomer and both executives for comment. Since November 2024, Cabot has held the title of Astronomer's Chief People Officer. According to the site's website, the tech company aims to empower data teams to bring mission-critical software, analytics and AI to life. Coldplay Fan Addresses Posting Jumbotron Video of Astronomer Executives: 'Play Stupid Games' 'I prefer to think of my role as people strategy versus traditional human resource,' Cabot said in a press release at the time of her hiring. 'I was energized in my conversations with Andy and the Astronomer leadership team about the opportunities that exist here.' Andy also expressed his excitement at the company's new hire. 'Kristin's exceptional leadership and deep expertise in talent management, employee engagement and scaling people strategies will be critical as we continue our rapid trajectory,' he said. 'She is a proven leader at multiple growth-stage companies and her passion for fostering diverse, collaborative workplaces makes her a perfect fit for Astronomer.' Solve the daily Crossword